Global Scopolamine Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Dosage Form;

Tablet, Syrup, Patch, Injection, and Others

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Route of Administration;

Topical, Oral, and Parenteral

By Application;

Motion Sickness, Postoperative Nausea, and Vomiting

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn419439961 Published Date: May, 2025 Updated Date: June, 2025

Scopolamine Market Overview

Scopolamine Market (USD Million)

Scopolamine Market was valued at USD 4,525.56 million in the year 2024. The size of this market is expected to increase to USD 6,183.46 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.6%.


Global Scopolamine Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 4.6 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.6 %
Market Size (2024)USD 4,525.56 Million
Market Size (2031)USD 6,183.46 Million
Market ConcentrationHigh
Report Pages334
4,525.56
2024
6,183.46
2031

Major Players

  • Baxter International Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemicals Corporation

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Scopolamine Market

Fragmented - Highly competitive market without dominant players


The scopolamine market is on a strong growth trajectory, propelled by its versatile applications across various industries. Derived from plants like deadly nightshade, scopolamine is a potent alkaloid primarily used in the pharmaceutical sector for its antiemetic and anticholinergic properties. It is crucial in treating motion sickness, nausea, and vomiting, particularly among chemotherapy patients or those susceptible to seasickness. In 2024, the pharmaceutical sector held a dominant share, contributing approximately 60% to the scopolamine market, highlighting the compound's significant role in modern medical treatments. Furthermore, scopolamine's expanding use in psychiatric treatments further enhances its relevance in contemporary healthcare.

Beyond its established pharmaceutical applications, scopolamine is increasingly popular in the travel and tourism industry as a reliable remedy for motion sickness. The rising demand for cruise vacations and adventure tourism has spurred the need for scopolamine-based products. This demand surge is linked to a broader consumer trend, with 15% more travelers seeking experiences prone to motion sickness, such as long-haul flights and cruises. Additionally, the rapid development of virtual reality (VR) technology has introduced new opportunities for scopolamine, with developers incorporating it into VR solutions for motion sickness relief, thus opening additional growth avenues.

Despite its positive growth prospects, several challenges may impact the scopolamine market. Stringent production and distribution regulations, along with the emergence of alternative therapies, could potentially slow market expansion in certain regions. Nevertheless, ongoing collaborations among industry leaders and continuous research into innovative applications are expected to mitigate these barriers.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Dosage Form
    2. Market Snapshot, By Distribution Channel
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By Application
    5. Market Snapshot, By Region
  4. Scopolamine Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing healthcare expenditure
        2. Growing prevalence of motion sickness
        3. Rising demand for chemotherapy-induced nausea treatment
      2. Restraints
        1. Stringent regulatory frameworks
        2. Side effects associated with scopolamine
        3. Limited awareness among consumers
      3. Opportunities
        1. Untapped markets in developing regions
        2. Novel formulations and delivery methods
        3. Focus on pediatric formulations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Scopolamine Market, By Dosage Form, 2021 - 2031 (USD Million)
      1. Tablet
      2. Syrup
      3. Patch
      4. Injection
      5. Others
    2. Scopolamine Market, By Distribution Channel, 2021 - 2031 (USD Million)

      1. Hospital Pharmacies

      2. Retail Pharmacies

      3. Online Pharmacies

    3. Scopolamine Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Topical
      2. Oral
      3. Parenteral
    4. Scopolamine Market, By Application, 2021 - 2031 (USD Million)
      1. Motion Sickness
      2. Postoperative Nausea
      3. Vomiting
    5. Scopolamine Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Integra LifeSciences Holding Corporation
      2. Alkaloids Corporation
      3. Boehringer Ingelheim
      4. Caleb Pharmaceuticals, Inc.
      5. Centroflora Group
      6. Fine Chemicals Corporation
      7. GlaxoSmithKline plc
      8. Henan Fusen Pharmaceutical Co., Ltd.
      9. Mylan N.V. (part of Viatris)
      10. Novartis AG
      11. Pfizer Inc.
      12. Pharmaceutical Associates, Inc.
      13. Phytex Australia
      14. Sun Pharmaceutical Industries Ltd.
      15. Teva Pharmaceutical Industries Ltd.
  7. Analyst Views
  8. Future Outlook of the Market